CFTR and cystic fibrosis: In the KONDUCT trial, Moss et al. explored its safety and efficacy in pwCF aged 6 years and older with at least one copy of the R117H-CFTR mutation (about 3% of the CF patient population), which is associated with both gating and conductance function [22].